irAEs according to Common Terminology Criteria for AE grading version 5.0 among 109 patients with high-risk DLBCL in CMR receiving atezolizumab consolidation
| Organ system . | Total n (%) . | Grade 1-2 n (%) . | Grade 3-4 n (%) . |
|---|---|---|---|
| Endocrinopathies | 10 (9.2) | 7 (6.4) | 3 (2.8) |
| Ocular toxicities | 3 (2.8) | 3 (2.8) | 0 (0) |
| Colitis | 2 (1.8) | 1 (0.9) | 1 (0.9) |
| Cutaneous | 2 (1.8) | 2 (1.8) | 0 (0) |
| Hepatitis | 1 (0.9) | 1 (0.9) | 0 (0) |
| Pneumonitis | 1 (0.9) | 1 (0.9) | 0 (0) |
| Neurological | 1 (0.9) | 0 (0) | 1 (0.9) |
| Total | 20 (18.3) | 15 (13.8) | 5 (4.5) |
| Organ system . | Total n (%) . | Grade 1-2 n (%) . | Grade 3-4 n (%) . |
|---|---|---|---|
| Endocrinopathies | 10 (9.2) | 7 (6.4) | 3 (2.8) |
| Ocular toxicities | 3 (2.8) | 3 (2.8) | 0 (0) |
| Colitis | 2 (1.8) | 1 (0.9) | 1 (0.9) |
| Cutaneous | 2 (1.8) | 2 (1.8) | 0 (0) |
| Hepatitis | 1 (0.9) | 1 (0.9) | 0 (0) |
| Pneumonitis | 1 (0.9) | 1 (0.9) | 0 (0) |
| Neurological | 1 (0.9) | 0 (0) | 1 (0.9) |
| Total | 20 (18.3) | 15 (13.8) | 5 (4.5) |